Epithelial–mesenchymal transition: role in cancer progression and the perspectives of antitumor treatment
About 90% of all malignant tumors are of epithelial nature. The epithelial tissue is characterized by a close interconnection between cells through cellcell interactions, as well as a tight connection with the basement membrane, which is responsible for cell polarity. These interactions strictly determine the location of epithelial cells within the body and are seemingly in conflict with the metastatic potential that many cancers possess (the main criteria for highly malignant tumors). Tumor dissemination into vital organs is one of the primary causes of death in patients with cancer. Tumor dissemination is based on the so-called epithelialmesenchymal transition (EMT), a process when epithelial cells are transformed into mesenchymal cells possessing high mobility and migration potential. More and more studies elucidating the role of the EMT in metastasis and other aspects of tumor progression are published each year, thus forming a promising field of cancer research. In this review, we examine the most recent data on the intracellular and extracellular molecular mechanisms that activate EMT and the role they play in various aspects of tumor progression, such as metastasis, apoptotic resistance, and immune evasion, aspects that have usually been attributed exclusively to cancer stem cells (CSCs). In conclusion, we provide a detailed review of the approved and promising drugs for cancer therapy that target the components of the EMT signaling pathways.
Top-30
Journals
|
1
2
3
|
|
|
International Journal of Molecular Sciences
3 publications, 12.5%
|
|
|
Journal of Clinical Medicine
2 publications, 8.33%
|
|
|
Cancers
2 publications, 8.33%
|
|
|
The Siberian Journal of Clinical and Experimental Medicine
2 publications, 8.33%
|
|
|
Drug Delivery
1 publication, 4.17%
|
|
|
Acta Naturae
1 publication, 4.17%
|
|
|
Frontiers in Immunology
1 publication, 4.17%
|
|
|
Animals
1 publication, 4.17%
|
|
|
Clinical and Translational Discovery
1 publication, 4.17%
|
|
|
ACS Omega
1 publication, 4.17%
|
|
|
Journal of Cellular and Molecular Medicine
1 publication, 4.17%
|
|
|
Cell Communication and Signaling
1 publication, 4.17%
|
|
|
European Journal of Medical Research
1 publication, 4.17%
|
|
|
Cancer Biomarkers
1 publication, 4.17%
|
|
|
The Scientific Notes of the Pavlov University
1 publication, 4.17%
|
|
|
Journal of Cellular Physiology
1 publication, 4.17%
|
|
|
Stem Cells International
1 publication, 4.17%
|
|
|
1
2
3
|
Publishers
|
1
2
3
4
5
6
7
8
|
|
|
MDPI
8 publications, 33.33%
|
|
|
Wiley
3 publications, 12.5%
|
|
|
Springer Nature
3 publications, 12.5%
|
|
|
Cardiology Research Institute
2 publications, 8.33%
|
|
|
Taylor & Francis
1 publication, 4.17%
|
|
|
Acta Naturae Ltd
1 publication, 4.17%
|
|
|
Frontiers Media S.A.
1 publication, 4.17%
|
|
|
American Chemical Society (ACS)
1 publication, 4.17%
|
|
|
Research Square Platform LLC
1 publication, 4.17%
|
|
|
SAGE
1 publication, 4.17%
|
|
|
FSBEI HE I.P. Pavlov SPbSMU MOH Russia
1 publication, 4.17%
|
|
|
Hindawi Limited
1 publication, 4.17%
|
|
|
1
2
3
4
5
6
7
8
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.